Bart Barlogie

76.1k total citations · 9 hit papers
704 papers, 42.4k citations indexed

About

Bart Barlogie is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Bart Barlogie has authored 704 papers receiving a total of 42.4k indexed citations (citations by other indexed papers that have themselves been cited), including 581 papers in Hematology, 356 papers in Molecular Biology and 263 papers in Oncology. Recurrent topics in Bart Barlogie's work include Multiple Myeloma Research and Treatments (547 papers), Protein Degradation and Inhibitors (157 papers) and Cancer Treatment and Pharmacology (108 papers). Bart Barlogie is often cited by papers focused on Multiple Myeloma Research and Treatments (547 papers), Protein Degradation and Inhibitors (157 papers) and Cancer Treatment and Pharmacology (108 papers). Bart Barlogie collaborates with scholars based in United States, Germany and Italy. Bart Barlogie's co-authors include John D. Shaughnessy, Guido Tricot, John Crowley, Elias Anaissie, Joshua Epstein, Frits van Rhee, Maurizio Zangari, Sundar Jagannath, Fenghuang Zhan and Nikhil C. Munshi and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Bart Barlogie

674 papers receiving 41.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

1999 2.0k citations Elias Anaissie, Madhav V. Dhodapkar et al. profile →
International Staging System for Multiple Myeloma

2005 1.9k citations Brian G.M. Durie, John J. Crowley et al. Journal of Clinical Oncology profile →
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma

2003 1.1k citations Fenghuang Zhan, Bart Barlogie et al. profile →
The molecular classification of multiple myeloma

2006 783 citations Fenghuang Zhan, Joshua Epstein et al. Blood profile →
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

2016 594 citations Brian G.M. Durie, Antje Hoering et al. profile →
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

2004 569 citations Sundar Jagannath, Bart Barlogie et al. profile →
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006 532 citations Bart Barlogie, Guido Tricot et al. profile →
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

2002 507 citations Fenghuang Zhan, Ralph D. Sanderson et al. Blood profile →
Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents

1984 500 citations Bart Barlogie et al. profile →

Peers

Countries citing papers authored by Bart Barlogie

Since Specialization

Citations

This map shows the geographic impact of Bart Barlogie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Barlogie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Barlogie more than expected).

Fields of papers citing papers by Bart Barlogie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Barlogie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Barlogie. The network helps show where Bart Barlogie may publish in the future.

Co-authorship network of co-authors of Bart Barlogie

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Barlogie. A scholar is included among the top collaborators of Bart Barlogie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Barlogie. Bart Barlogie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma 2024 ·American Journal of Hematology ·(unknown), (unknown), (unknown), Jiahui Liu, (unknown), (unknown), Yan Xu, Weiwei Sui, Shuhui Deng, Dehui Zou, (unknown), Shuhua Yi, Frits van Rhee, Bart Barlogie, John D. Shaughnessy, Kenneth C. Anderson, Fenghuang Zhan, Lugui Qiu, Gang An	7
2	Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up 2023 ·Blood Advances ·Samer Al Hadidi, (unknown), Carolina Schinke, Sharmilan Thanendrarajan, Clyde Bailey, Robert W. Smith, Susan Panozzo, Daisy Alapat, Michele Cottler‐Fox, (unknown), John D. Shaughnessy, (unknown), Jeffrey R. Sawyer, Bart Barlogie, Maurizio Zangari, Frits van Rhee	5
3	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Siyang Leng, Erin Moshier, Douglas Tremblay, Liangyuan Hu, Noa Biran, (unknown), Samir Parekh, (unknown), Deepu Madduri, Joshua Richter, Bart Barlogie, Sundar Jagannath, Ajai Chari	2
4	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Tarek H. Mouhieddine, Yasir Ahmad, Bart Barlogie, Sundar Jagannath, Julie Teruya‐Feldstein, Joshua Richter	3
5	Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia 2018 ·Clinical Cancer Research ·Mu Hao, Bart Barlogie, Guido Tricot, Lanting Liu, Lugui Qiu, John D. Shaughnessy, Fenghuang Zhan	8
6	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma 2018 ·Clinical Cancer Research ·Carolina Schinke, Pingping Qu, Syed J. Mehdi, Antje Hoering, Joshua Epstein, Sadie Johnson, Frits van Rhee, Maurizio Zangari, Sharmilan Thanendrarajan, Bart Barlogie, Faith E. Davies, Shmuel Yaccoby, Gareth J. Morgan	27
7	Deconvolution of the Immune Microenvironment Can Predict the Outcome of Myeloma Patients and Inform Potential Intervention Strategies 2017 ·Blood ·Samuel A. Danziger, Andrew Dervan, Frank Schmitz, Brian A. Walker, Wilbert B. Copeland, Alison Fitch, Kathryn J. Newhall, Cody Ashby, Michael Bauer, Bart Barlogie, (unknown), Matthew Trotter, (unknown), Alexander V. Ratushny, Gareth J. Morgan	1
8	Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma 2016 ·Clinical Cancer Research ·James E. McDonald, Marcus M. Kessler, (unknown), Amy Buros, (unknown), Sarah Waheed, Frits van Rhee, Maurizio Zangari, Christoph Heuck, Nathan Petty, Carolina Schinke, Sharmilan Thanendrarajan, Alan Mitchell, Antje Hoering, Bart Barlogie, Gareth J. Morgan, Faith E. Davies	92
9	Curing myeloma at last: defining criteria and providing the evidence 2014 ·Blood ·Bart Barlogie, Alan Mitchell, Frits van Rhee, Joshua Epstein, Gareth J. Morgan, John Crowley	169
10	Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 2012 ·Clinical Cancer Research ·Christoph Heuck, Jackie Szymonifka, (unknown), John D. Shaughnessy, Saad Z. Usmani, Frits van Rhee, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, Clyde Bailey, Joshua Epstein, Antje Hoering, John Crowley, Bart Barlogie	13
11	Cure Models as a Useful Statistical Tool for Analyzing Survival 2012 ·Clinical Cancer Research ·Megan Othus, Bart Barlogie, Michael LeBlanc, John J. Crowley	151
12	Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences 2010 ·Journal of Clinical Oncology ·Bart Barlogie, Michel Attal, John Crowley, Frits van Rhee, Jackie Szymonifka, Philippe Moreau, Brian G.M. Durie, Jean‐Luc Harousseau	103
13	Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma 2009 ·Molecular Cancer Therapeutics ·Frits van Rhee, Susann Szmania, Myles Dillon, (unknown), Xin Li, (unknown), Tarun K. Garg, Jumei Shi, Amberly Moreno-Bost, (unknown), Balaji Balasa, (unknown), Debra T. Chao, Audie Rice, Fenghuang Zhan, John D. Shaughnessy, Bart Barlogie, Shmuel Yaccoby, Daniel Afar	142
14	International prognostic scoring system for Waldenström macroglobulinemia 2009 ·Blood ·Pierre Morel, Alain Duhamel, Paolo G. Gobbi, Meletios Α. Dimopoulos, Madhav V. Dhodapkar, Jason McCoy, John Crowley, Enrique M. Ocio, Ramón García‐Sánz, Steven P. Treon, Véronique Leblond, Robert A. Kyle, Bart Barlogie, Giampaolo Merlini	228
15	Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis 2009 ·JNCI Journal of the National Cancer Institute ·Guido Tricot, Steven E. Kern, Bart Barlogie	5
16	Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma 2008 ·Clinical Cancer Research ·Bart Burington, Bart Barlogie, Fenghuang Zhan, John Crowley, John D. Shaughnessy	35
17	Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling 2007 ·Clinical Cancer Research ·Jeffrey Haessler, John D. Shaughnessy, Fenghuang Zhan, John Crowley, Joshua Epstein, Frits van Rhee, Elias Anaissie, Mauricio Pineda‐Roman, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, Guido Tricot, Bart Barlogie	75
18	Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications 2007 ·Cancer ·Marisa H. Miceli, Johan Maertens, (unknown), Monica Grazziutti, Gail L. Woods, (unknown), Bart Barlogie, Elias Anaissie	122
19	High heparanase activity in multiple myeloma is associated with elevated microvessel density. 2003 ·PubMed ·Thomas J. Kelly, Hua‐Quan Miao, Yang Yang, Elizabeth Navarro, Paul Kussie, Yan Huang, Veronica MacLeod, (unknown), Lija Joseph, Fenghuang Zhan, Maurizio Zangari, Bart Barlogie, John D. Shaughnessy, Ralph D. Sanderson	146
20	Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients 2003 ·Blood ·E. Anaissie, Joth Jacobson, Athanasios Fassas, Maurizio Zangari, Raymond Thertulien, (unknown), (unknown), Guido Tricot, (unknown), (unknown), Klaus Hollmig, Bart Barlogie	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact